This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 9 min This content is machine translated System therapy for psoriasis Expanded possibilities thanks to practical innovations Compared to the past, there are now more and more effective systemic therapies available. This has been helped by a surge in innovation that has produced a wide range of…
View Post 2 min This content is machine translated Severe asthma and psoriasis Biologics combination leads to success Biologics are now established treatment options, particularly for severe courses of the disease. However, there is little data on the the efficacy and safety of simultaneous administration of several biologics…
View Post 5 min This content is machine translated Biologics therapy for psoriasis Better outcomes through innovative methods of therapy management Personalized medicine is also becoming increasingly important in the field of inflammatory skin diseases. Currently, IL-17 and IL-23 inhibitors are most effective in moderate to severe psoriasis, but the response…
View Post 8 min This content is machine translated Psoriasis vulgaris Practice-oriented recommendations for system therapy Fortunately, developments in recent years have led to the effective treatment of many patients with moderate to severe psoriasis. In addition to classical immunosuppressants, several biologics and a small molecule…
View Post 4 min This content is machine translated Biologics for psoriasis “Drug Survival” under the microscope The era of biologics has revolutionized the treatment options for patients with moderate to severe psoriasis in recent decades. Drug survival is an indicator of the longer-term efficacy and safety…
View Post 8 min This content is machine translated Plaque psoriasis Updated guideline recommendations for children and adolescents Early treatment in children and adolescents with psoriasis is an important supply target. The updated s2k guideline provides evidence-based decision support for the selection of appropriate therapy. In the new edition…
View Post 3 min This content is machine translated Plaque psoriasis 5-Year Data on Ixekizumab: Patients Benefit Over the Long Term Continuous therapy with the anti-IL17 antibody ixekizumab has shown sustained long-term improvements in itch, skin pain, and health-related quality of life in patients with moderate to severe plaque psoriasis. Patients…
View Post 12 min This content is machine translated Axial spondyloarthritis and psoriatic arthritis Effective and efficient against pain The anti-IL-17A monoclonal antibody ixekizumab has already been approved since 2016 for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. In 2020, axial spondyloarthritis (axSpA) was added… CME-Test
View Post 4 min This content is machine translated Moderate to severe plaque psoriasis High patient satisfaction thanks to rapid and sustained efficacy of ixekizumab From the patient’s point of view, a rapid onset of action is one of the most important treatment goals, along with appearance-free skin. Both the data from the UNCOVER-3 study…
